Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Peer-to-peer discussions have further fueled interest in microdosing, with compounded vials offering greater dosing flexibility than fixed-dose pens
While tirzepatide (Zepbound and Mounjaro) currently leads in terms of average weight loss in approved medications, CagriSema could become a strong competitor once Phase 3 results are released
However, 55.7% of these patients either remained around the weight they were at when stopping the medication or continued to lose additional weight
Em dezembro de 2025 , a Lilly divulgou os resultados principais do estudo TRIUMPH4, envolvendo pacientes com obesidade ou sobrepeso e osteoartrite de joelho
